Shield Therapeutics PLC (AIM: STX, OTCQX: SHIEF) shares surged 47% following the release of impressive second-quarter trading results.
MiNK the Agenus Cell Therapy spinoff makes its mark on Wall Street with $40M IPO
MiNK Therapeutics secured its Nasdaq spot Friday with a $40 million initial public offer. This was to allow MiNK Therapeutics to move its lead candidate through phase I trials in